Medpace Holdings, Inc. $MEDP Stock Position Raised by Hancock Whitney Corp

Key Points

• Hancock Whitney Corp increased its stake in Medpace Holdings, Inc. by 3.9% during Q1, owning approximately $15.3 million worth of shares.
• Analysts' ratings for Medpace have been mixed, with two Buy ratings, eleven Hold ratings, and three Sell ratings, while its average target price is $412.73.
• Insider selling has been significant, with CFO Kevin M. Brady and President Jesse J. Geiger both selling large quantities of stock, totaling over $24 million in recent transactions.

Hancock Whitney Corp lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,206 shares of the company's stock after purchasing an additional 1,902 shares during the period. Hancock Whitney Corp owned approximately 0.17% of Medpace worth $15,297,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Whittier Trust Co. raised its holdings in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares during the period. Benjamin Edwards Inc. lifted its position in shares of Medpace by 3.1% in the 1st quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock valued at $366,000 after acquiring an additional 36 shares in the last quarter. Assetmark Inc. lifted its position in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in Medpace by 6.4% in the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after purchasing an additional 47 shares during the period. Finally, Park Avenue Securities LLC raised its stake in Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after purchasing an additional 48 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on MEDP shares. Rothschild & Co Redburn cut Medpace from a "buy" rating to a "neutral" rating and raised their target price for the stock from $342.00 to $474.00 in a research report on Wednesday. UBS Group cut Medpace from a "neutral" rating to a "sell" rating and lifted their target price for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Mizuho raised their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average target price of $412.73.

Insiders Place Their Bets

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Jesse J. Geiger sold 41,801 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president owned 36,503 shares in the company, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 151,266 shares of company stock worth $69,311,427 in the last three months. 20.30% of the stock is owned by insiders.

Medpace Stock Up 1.7%

Shares of MEDP opened at $481.23 on Thursday. The firm has a market cap of $13.52 billion, a price-to-earnings ratio of 35.78, a price-to-earnings-growth ratio of 2.99 and a beta of 1.44. The company's fifty day moving average is $405.65 and its 200-day moving average is $342.20. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period in the prior year, the company posted $2.75 earnings per share. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.